An Ottawa life sciences company that makes a natural health compound designed to boost the immune systems of livestock reported a significant jump in revenues and secured the largest recurring order in its history in the second quarter.
Avivagen, which trades on the TSX Venture Exchange in Canada and the OTCQB Venture Market in the U.S., said it had revenues of nearly $160,000 in the three-month period ending April 30, up from just under $30,000 a year earlier.
The firm also posted a loss of $2.2 million, compared with a loss of $1.2 million in the second quarter of 2020.
(Sponsored)
How Carleton is using simulation and visualization to improve training, design and human performance
From healthcare to aviation to architecture, simulation and visualization tools have become an essential part of training, analysis and decision-making in sectors that rely on precision. At Carleton University, researchers
For the fifth year in a row, Ottawa will become the epicentre of Canadian culinary excellence in late January. Chefs from Ottawa, Vancouver, Edmonton, Calgary, Saskatoon, Winnipeg, Toronto, Montreal, Moncton
Avivagen, which produces supplements aimed at replacing antibiotics in cattle feed, also said it landed an 18-month contract to supply fourth tonnes of its OxC-beta Livestock product per month to a customer in Mexico. At 64.5-tonnes, the deal is the Ottawa firm’s biggest ever.
The company also announced this week it has closed a $7.5-million bought-deal offering it announced earlier this year. Avivagen is now working on a new version of the product aimed at humans that it hopes will help it finally achieve its long-anticipated market breakthrough.
